secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONCERT PHARMACEUTICALS, INC. (—)
CIK:        0001367920
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001193125-23-060815
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sun Pharma completes acquisition of Concert Pharmaceuticals for $8.00/share plus CVRs
--------------------------------------------------------------------------------

- Offer expired with 48,220,511 shares tendered (~75.2%); all conditions satisfied, merger effective March 6, 2023.
- Concert stockholders receive $8.00 per share plus one CVR per share; CVRs pay up to $3.50 per CVR based on deuruxolitinib net sales milestones.
- CVR milestones: $1.00 if net sales exceed $100M by March 31, 2027; $2.50 if net sales exceed $500M by Dec 31, 2029.
- Concert's common stock delisted from Nasdaq; directors and officers (including CEO Roger Tung) resigned, replaced by Sun Pharma appointees.
- Transaction bonuses of $50,000 each approved for CFO Marc Becker and Chief Development Officer James Cassella.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367920/000119312523060815/0001193125-23-060815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367920/000119312523060815/d470195d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-060815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer